– New appointments as part of the Firm’s strategic progress strategies to accelerate transformation towards commercialization
– Dr. Andrew Zhu, an internationally renowned oncologist, appointed as President and board director to direct the Company’s R&D business, concentrating on world pipeline progress
– Founder and Chairman Dr. Jingwu Zang named Acting Chief Govt Officer
– Newly set up Commercialization Executive Council to catalyze corporate enhancement and partnership specials for commercialization
– I-Mab to host a call for buyers on December 21, 2021, at 8:00 a.m. ET
SHANGHAI, China and GAITHERSBURG, Md., Dec. 20, 2021 /PRNewswire/ — I-Mab (the “Corporation”) (Nasdaq: IMAB), a scientific-stage biopharmaceutical enterprise dedicated to the discovery, progress, and commercialization of novel biologics, right now introduced strategic management adjustments and a new governance initiative designed to aid its world-wide pipeline development and speed up its ongoing transformation to an integrated worldwide biopharma organization. The announcement is an integral section of I-Mab’s strategic growth programs to place the Organization for the following phase of progress.
Dr. Andrew Zhu, an internationally renowned oncologist, joined I-Mab as President and board director to lead the Firm’s global R&D business, focusing on delivering the pipeline milestones and maximizing clinical improvement functionality in the U.S. and China. With his loaded working experience in global drug growth, Dr. Zhu has labored with numerous pharmaceutical corporations, which include Merck, Eli Lilly, Roche, and Bayer. He has led and participated in much more than 50 world medical trials. Dr. Zhu will be dependent in Shanghai and report specifically to company Founder and Chairman Dr. Jingwu Zang.
“We’re excited to welcome Dr. Zhu to I-Mab. Dr. Zhu is an recognized and earth-renowned professional in clinical oncology with an spectacular observe report in medical exploration and clinical development of novel prescription drugs. As I-Mab’s pipeline has arrived at a essential evidence-of-concept and registrational phase, Dr. Zhu’s deep clinical exploration skills and novel drug progress working experience at the world’s top academic institutions will be important to guaranteeing that we produce the prepared scientific milestones successfully and further more increase our aggressive place in the global area of immuno-oncology,” Dr. Zang commented.
“As a actually world wide biotech corporation with a wealthy and impressive pipeline, I-Mab has attained remarkable achievements within just a brief period of time. I am incredibly excited to just take on this part at I-Mab in which I can effectively commit my passion and oncology know-how in major the R&D crew to the up coming degree of scientific enhancement capacity and competitiveness and accelerating the shipping and delivery of I-Mab’s worldwide progressive scientific compounds to sufferers in need to have around the planet,” mentioned Dr. Zhu. Formerly, Dr. Zhu served as a member of I-Mab’s Scientific Advisory Board.
To greater put together the transition toward the next period of advancement, the Board has appointed Dr. Jingwu Zang, Founder and Chairman of I-Mab, as Acting Chief Govt Officer, efficient January 1, 2022. Dr. Zang started I-Mab Biopharma and has served as Chairman and CEO due to the fact 2016 (remaining as Chairman due to the fact Oct 2019). Under his vision and leadership, the Firm has set an ambitious agenda to focus on innovation in immuno-oncology and has speedily emerged as an impressive scientific stage biotech with globally competitive belongings, such as lemzoparlimab (CD47 antibody), uliledlimab (CD73 antibody) and plonmarlimab (GM-CSF antibody), which are now among the international front-runners.
“In a quick period of time of time, I-Mab has progressed to become a major world wide player in immuno-oncology industry with a world name for its pursuit of very first-in-course and ideal-in-class therapies. We rely on that Dr. Zang will continue to help propel the Company to new ranges and assure a productive transition,” reported Mr. Wei Fu, Director and Chairman of the Nominating and Corporate Governance Committee of I-Mab.
With a well-positioned administration crew in position, the Business is progressing speedily toward its staged transformational aim as governed by a freshly set up Commercialization Executive Council (CEC) to push partnerships, corporate investment and possible merger & acquisition. The CEC provides a critical inner cross-functional governance overall body dependable for scheduling and overseeing the comprehensive spectrum of the Firm’s commercialization activities. The essential customers of the CEC are composed of Mr. Jielun Zhu (Chief Strategy Officer), Mr. Yifei Zhu (Main Business Officer), Dr. Weimin Tang (Main Company Officer), Dr. Andrew Zhu (President) and Mr. John Long (Main Economical Officer).
As section of this management transform, Dr. Joan Shen, will phase down as CEO on December 31, 2021 to go after other passions.
“On behalf of the Board, I would like to express our gratitude to Joan for her impactful contributions to the Organization around the earlier several years. She was instrumental to the progress that we have made to progress our globally competitive pipeline, laying a solid foundation for I-Mab’s upcoming,” stated Dr. Zang.
I-Mab Meeting Connect with Facts
I-Mab will also host an investor call on December 21, 2021, at 8:00 a.m. ET to introduce the new administration customers.
About Dr. Andrew Zhu
Dr. Andrew Zhu is an internationally renowned oncologist. He was Professor of Medicine at Harvard Medical Faculty and served as Director of Liver Most cancers Exploration at Massachusetts Normal Medical center (MGH) Most cancers Heart. In collaboration with his colleagues, Dr. Zhu established and led the multidisciplinary liver cancer clinic at the MGH and made one of the most productive scientific and translational analysis packages in hepatobiliary cancers in the U.S. Prior to becoming a member of I-Mab, Dr. Zhu was Director of Jiahui International Cancer Center of the Jiahui Worldwide Hospital in Shanghai, China and subsequently served as Chief Scientific Officer of Jiahui Health.
Dr. Zhu has an outstanding track history in scientific progress of impressive oncology medication. He has led early-stage growth of numerous specific therapy and immuno-oncology medications for liver cancer and various pivotal scientific tests that led to regulatory acceptance by the Food and drug administration, like the improvement of pembrolizumab (KEYNOTE-224) and ramucirumab (Attain-2) for advanced liver cancer, and the profitable advancement of the to start with IDH-1 inhibitor (Ivosidenib) for cholangiocarcinoma. Dr. Zhu also served on the Steering Committee of numerous period III trials in the advancement of mixture immunotherapies for liver most cancers, such as atezolizumab put together with bevacizumab. He has also served on the committee for the institution of a lot of world HCC Clinical Trial Design and style and Practice Suggestions, together with the NCCN Pointers for Hepatobiliary Cancers, AASLD Pointers for the Treatment method of Hepatocellular Carcinoma, and ASCO Rules on Systemic Treatment for Innovative Hepatocellular Carcinoma.
Dr. Zhu gained his health-related degree from Peking University Wellness Science Middle and his Ph.D. from Columbia College. Adhering to his postdoctoral research instruction at Harvard Medical College. he accomplished his scientific teaching in interior drugs at Yale New Heaven Healthcare facility, Yale Faculty of Medication, and a fellowship in Hematology-Oncology at Memorial Sloan-Kettering Cancer Centre. Dr. Zhu has printed much more than 300 scientific papers and assessments in major intercontinental journals these types of as New England Journal of Medicine, Lancet, JAMA, Character Medication, Lancet Oncology, Journal of Clinical Oncology and Most cancers Discovery.
I-Mab (Nasdaq: IMAB) is an innovation-pushed world wide biopharma enterprise centered on the discovery, improvement and commercialization of novel and really differentiated biologics for immuno-oncology and autoimmune ailments. The Company’s mission is to convey transformational medicines to sufferers about the world by innovation. I-Mab’s globally aggressive pipeline of more than 20 clinical and preclinical-phase drug candidates is driven by its internal discovery and world-wide partnerships for in-licensing, centered on the Company’s Speedy-to-Proof-of-Concept and Quickly-to-Market growth procedures. The Corporation is progressing from a clinical-stage biotech company into a thoroughly integrated global biopharmaceutical corporation with reducing-edge R&D abilities, a planet-course GMP production facility, and business capability. I-Mab has set up its world wide footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States. For a lot more information and facts, remember to visit http://ir.i-mabbiopharma.com and adhere to I-Mab on LinkedIn, Twitter , and WeChat.
I-Mab Ahead-Wanting Statements
This press release incorporates particular disclosures which consist of “forward-hunting statements.” You can recognize forward-looking statements since they incorporate phrases these types of as “anticipate” and “anticipated.” Ahead-seeking statements are centered on I-Mab’s current anticipations and assumptions. For the reason that ahead-seeking statements relate to the upcoming, they are subject to inherent uncertainties, challenges and changes in circumstances that may well vary materially from those people contemplated by the ahead-searching statements, which are neither statements of historic truth nor assures or assurances of long run general performance. Significant things that could lead to true results to vary materially from these in the forward-looking statements are established forth in filings with the U.S. Securities and Trade Fee. I-Mab undertakes no obligation to publicly update or revise any forward-on the lookout statements, whether or not as a end result of new information and facts, foreseeable future gatherings or if not, except as may possibly be essential by regulation.
For additional facts, you should contact:
John Extended, Chief Financial Officer
E-mail: [email protected]
Business line: +86 21 6057 8000
Gigi Feng, Main Communications Officer
E-mail: [email protected]
Office line: +86 21 6057 5709
The Piacente Group, Inc.
E-mail: [email protected]
Business office line: + 86 21 6039 8363